{"protocolSection":{"identificationModule":{"nctId":"NCT01251367","orgStudyIdInfo":{"id":"Y-55-52120-142"},"secondaryIdInfos":[{"id":"2009-017723-26","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Ipsen","class":"INDUSTRY"},"briefTitle":"Dysport® Adult Lower Limb Spasticity Follow-on Study","officialTitle":"A Phase III, Prospective, Multicentre, Open Label, Extension Study, to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Lower Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury"},"statusModule":{"statusVerifiedDate":"2022-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-06"},"primaryCompletionDateStruct":{"date":"2015-04","type":"ACTUAL"},"completionDateStruct":{"date":"2015-04","type":"ACTUAL"},"studyFirstSubmitDate":"2010-11-25","studyFirstSubmitQcDate":"2010-11-30","studyFirstPostDateStruct":{"date":"2010-12-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-07-03","resultsFirstSubmitQcDate":"2017-11-08","resultsFirstPostDateStruct":{"date":"2017-11-09","type":"ACTUAL"},"dispFirstSubmitDate":"2015-04-28","dispFirstSubmitQcDate":"2015-04-28","dispFirstPostDateStruct":{"date":"2015-05-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-09-15","lastUpdatePostDateStruct":{"date":"2022-09-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ipsen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles."},"conditionsModule":{"conditions":["Post-stroke Spasticity","Spasticity Post-Traumatic Brain Injury"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":352,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dysport®","type":"EXPERIMENTAL","description":"Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.","interventionNames":["Biological: Botulinum toxin type A"]}],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","description":"I.M. (intramuscular) injection on day 1 of each treatment cycle.","armGroupLabels":["Dysport®"],"otherNames":["AbobotulinumtoxinA (Dysport®)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)","description":"Adverse events (AEs) were monitored from the time that the subject gave informed consent to the end of the study/early withdrawal (EOS/EW). An AE was reported as a TEAE if it was not present prior to study treatment administration in Study 140, or if it was present prior to study treatment in Study 140 but the intensity increased during the treatment phase of this study. Adverse events of special interest (AESIs) were identified as those assessed as being due to remote spread of effect of Dysport®, or any AE that was assessed as a hypersensitivity reaction. TEAEs, treatment related TEAEs, severe TEAEs, TEAEs leading to death, TEAEs leading to withdrawal, treatment emergent AESIs, and serious adverse events (SAEs) are summarised by treatment cycle.","timeFrame":"Up to EOS (maximum duration of 52 weeks)."},{"measure":"Mean Change From Baseline to Week 4 in Systolic and Diastolic Blood Pressure (BP)","description":"Systolic and diastolic BP were recorded at baseline and at each subsequent study visit. BP was measured with the subject in a sitting position after resting for 3 minutes. Mean change in BP from baseline at Week 4 is reported per cycle.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Heart Rate (HR)","description":"HR was recorded at baseline and at each subsequent study visit. HR was measured with the subject in a sitting position after resting for 3 minutes. Mean change in HR from baseline at Week 4 is reported per cycle.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Red Blood Cell (RBC) Count","description":"Blood samples for RBC count were taken at baseline, at Week 4, and at EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Haemoglobin and Mean Corpuscular Haemoglobin Concentration (MCHC)","description":"Blood samples for haemoglobin and MCHC were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Haematocrit","description":"Blood samples for haematocrit were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Mean Corpuscular Haemoglobin (MCH)","description":"Blood samples for MCH were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Mean Corpuscular Volume (MCV)","description":"Blood samples for MCV were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in White Blood Cell (WBC) Count, Neutrophils, Lymphocytes and Platelets","description":"Blood samples for WBC count with differentials (neutrophils, lymphocytes) and platelet count were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Alkaline Phosphatase (ALP), Gamma Glutamyl Transferase (GGT), Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT)","description":"Blood samples were taken at baseline, at Week 4, and at the EOS/EW for analysis of the following clinical chemistry parameters: ALP, GGT, SGOT and SGPT. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Total Bilirubin and Creatinine","description":"Blood samples for clinical chemistry analysis of total bilirubin and creatinine were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Blood Urea Nitrogen (BUN) and Fasting Blood Glucose","description":"Blood samples for analysis of BUN and fasting blood glucose levels were taken at baseline, at Week 4 and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Presence of Botulinum Toxin Type A (BTX-A) Neutralising Putative Antibodies (NAbs) Following Injection of Dysport®","description":"Blood samples were collected at baseline, Week 4 and at EOS/EW to test for the presence of BTX-A antibodies. The number of subjects who were either NAb positive at baseline or negative at baseline but then positive following injection of Dysport® were reported.","timeFrame":"At Week 4"},{"measure":"Mean Change From Baseline to Week 4 in 12-Lead Electrocardiogram (ECG)","description":"12-lead ECG tracing was performed at baseline, at Week 4 of each cycle and at EOS/EW. The 12-lead ECG recordings were performed at a paper speed of 25 millimetres/second (mm/s), recorded with the subject in a supine position after 5 minutes rest. The ECG parameters; QT Duration, QT interval corrected with Fridericia's method (QTcF), QT interval corrected with Bazett's method (QTcB), QRS duration and PR duration were recorded and outcome measure is reported per cycle as change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"}],"secondaryOutcomes":[{"measure":"Mean Change From Baseline to Week 4 in the Modified Ashworth Scale (MAS) Score Measured in the Gastrocnemius-soleus Complex (GSC) (Knee Extended)","description":"Muscle tone in the treated limb was assessed by MAS in the GSC (with the knee extended) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion (ROM)), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as mean change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in the MAS Measured in the Soleus Muscle (Knee Flexed)","description":"Muscle tone in the treated limb was assessed by MAS in the soleus muscle (with the knee flexed) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the ROM), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as mean change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Percentage of Subjects With At Least a 1 or 2 Grade Reduction in the MAS Measured in the GSC (Knee Extended) at Week 4","description":"Muscle tone in the treated limb was assessed by MAS in the GSC (with the knee extended) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the ROM), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as the percentage of subjects with at least a 1 grade reduction or 2 grades reduction in MAS score at Week 4.","timeFrame":"Week 4 of each cycle"},{"measure":"Percentage of Subjects With At Least a 1 or 2 Grade Reduction in the MAS Measured in the Soleus Muscle (Knee Flexed) at Week 4","description":"Muscle tone in the treated limb was assessed by MAS in the soleus muscle (with the knee flexed) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the ROM), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as the percentage of subjects with at least a 1 grade reduction or 2 grades reduction in MAS score at Week 4.","timeFrame":"Week 4 of each cycle"},{"measure":"Physician's Global Assessment (PGA) of Treatment Response at Week 4","description":"An assessment of overall treatment response was conducted by the investigator at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The investigator rated the response to treatment in the subject's lower limb after injection of Dysport® relative to the status at the baseline. Answers were made on a nine-point rating scale: -4=markedly worse, -3=much worse, -2=worse, -1=slightly worse, 0=no change, +1=slightly improved, +2=improved, +3=much improved, +4=markedly improved. The mean PGA scores per cycle at Week 4 were reported.","timeFrame":"Week 4 of each cycle"},{"measure":"Percentage of Subjects With a Score of at Least +1 on the PGA Scale at Week 4","description":"An assessment of overall treatment response was conducted by the investigator at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The investigator rated the response to treatment in the subject's lower limb after injection of Dysport® relative to the status at the baseline. Answers were made on a nine point rating scale: -4=markedly worse, -3=much worse, -2=worse, -1=slightly worse, 0=no change, +1=slightly improved, +2=improved, +3=much improved, +4=markedly improved. The percentage of responders with a PGA score of +1 or greater are reported at Week 4.","timeFrame":"Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in the Range of Active Ankle Dorsiflexion Both With the Knee Flexed and With the Knee Extended","description":"Range of active dorsiflexion of the ankle joint of the treated limb, measured using a goniometre, both with the knee flexed (90°) and extended, was used to assess treatment response. The measurements were obtained at the end of baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Lower Limb Pain","description":"The intensity of lower limb pain in the treated limb was evaluated by the subject using the Scale of Pain Intensity (SPIN) which provided a pictorial representation of pain in a 6-point graphic scale with the degree of red shading inside a circle representing the intensity of pain. The bottom and top of the scale are anchored by two extremes: 'no pain' (circle with no red shading and scored as 0) and 'pain as bad as it could be' (circle completely red and scored as 5), marked with either verbal or visual cues. The intervening points are represented by red circles increasing proportionally in size. The subject marks the circle that best indicates their pain intensity. The SPIN assessments were obtained at baseline, Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at the EOS/EW. The mean changes from baseline in subjects with a baseline SPIN Score \\>0 at Week 4 was reported per cycle.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Short Form (36) Health Survey (SF-36) Quality of Life (QoL)","description":"Subjects were asked to complete the SF-36 health surveys prior to the study treatment at baseline, at Week 4 and at the EOS/EW visit. The SF-36 is a generic non preference based health status measure. This instrument assessed subject health across 8 variable dimensions, which are specific health domains such as physical functioning, social functioning and vitality. Each variable item score is coded and turned into a 0-100 scale where 0 indicates the worst and 100 indicates the best possible health state for both the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the questionnaire. The mean change in the PCS and MCS from baseline to Week 4 are reported.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline in European Quality of Life - 5 Dimensions, 5 Level (EQ-5D-5L) QoL","description":"Subjects were asked to complete the EQ-5D-5L QoL questionnaire prior to the study treatment at baseline, at Week 4 and at EOS/EW visit. The EQ-5D-5L index is a generic preference based measure of health related QoL producing utility scores that represent subject preferences for particular health states. This instrument rated subject health state looking at 5 specific dimensions such as mobility, self-care, usual activity, pain/discomfort and anxiety/ depression and scored their general health state. Each dimension has 5 levels of severity: no problems, slight problems, moderate problems, severe problems and extreme problems, rated from 1 to 5 (best to worst). In addition, a visual analogue scale (VAS) ranging from 0 to 100 was also included for the patients to summarize their overall health status, where 0 is the worst and 100 the best possible health state. The mean change in pain and discomfort and VAS scores from baseline to Week 4 are reported.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Walking Speed (WS)","description":"All WS tests were conducted without walking aids over a distance of 10 metres at both a comfortable WS and at maximal WS. Evaluations of WS were made barefoot and with shoes on, at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Step Length","description":"All WS tests were conducted without walking aids over a distance of 10 metres at both a comfortable WS and at maximal WS. Evaluations of step length were made barefoot and with shoes on, at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Cadence","description":"All WS tests were conducted without walking aids over a distance of 10 metres at both a comfortable WS and at maximal WS. Evaluations of cadence were made barefoot and with shoes on, at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Angle of Arrest (XV1), Angle of Catch (XV3) and Spasticity Angle (X) in the GSC (Knee Extended)","description":"Spasticity in the treated limb was assessed using the Tardieu Scale (TS) for the GSC (knee extended). The TS is administered by applying passive stretch to a muscle group at two velocities. Slow speed of muscle stretch measures the range of passive motion. During a slow stretching movement, the examiner determines the angle of movement arrest, either due to subject discomfort or a mechanical resistance. The same movement is repeated at high velocity (as fast as possible) to determine the angle of catch and release. The angle of movement arrest at slow velocity (XV1) and the angle of catch at fast speed (XV3) were recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The spasticity angle (X) was calculated as the difference between XV1 and XV3. Mean changes in Angles XV1, XV3 and X from baseline to Week 4 are reported per cycle.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Spasticity Grade (Y) in the GSC (Knee Extended)","description":"Spasticity in the treated limb was assessed using the TS for the GSC (knee extended). The TS is administered by applying passive stretch to a muscle group. The spasticity grade (Y) assesses quality of muscle reaction on a 5-point scale (measured at fast speed): 0 =No resistance throughout passive movement, 1=slight resistance throughout passive movement, 2=clear catch at precise angle, interrupting passive movement, followed by release, 3=fatigable clonus (less than 10 seconds when maintaining pressure) occurring at a precise angle, followed by release. 4=unfatigable clonus (more than 10 seconds when maintaining pressure) occurring at precise angle. Spasticity grade (Y) was recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. Mean changes in spasticity grade (Y) from baseline to Week 4 are reported per cycle.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Angle of Arrest (XV1), Angle of Catch (XV3) and Spasticity Angle (X) in the Soleus Muscle (Knee Flexed)","description":"Spasticity in the treated limb was assessed using the TS for the soleus muscle (knee flexed). The TS is administered by applying passive stretch to a muscle group at two velocities. Slow speed of muscle stretch measures the range of passive motion. During a slow stretching movement, the examiner determines the angle of movement arrest, either due to subject discomfort or a mechanical resistance. The same movement is repeated at high velocity (as fast as possible) to determine the angle of catch and release. The angle of movement arrest at slow velocity (XV1) and the angle of catch at fast speed (XV3) were recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The spasticity angle (X) was calculated as the difference between XV1 and XV3. Mean changes in Angles XV1, XV3 and X from baseline to Week 4 are reported per cycle.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Mean Change From Baseline to Week 4 in Spasticity Grade (Y) in the Soleus Muscle (Knee Flexed)","description":"Spasticity in the treated limb was assessed using the TS for the soleus muscle (knee flexed). The TS is administered by applying passive stretch to a muscle group. The spasticity grade (Y) assesses quality of muscle reaction on a 5-point scale (measured at fast speed): 0 =No resistance throughout passive movement, 1=slight resistance throughout passive movement, 2=clear catch at precise angle, interrupting passive movement, followed by release, 3=fatigable clonus (less than 10 seconds when maintaining pressure) occurring at a precise angle, followed by release. 4=unfatigable clonus (more than 10 seconds when maintaining pressure) occurring at precise angle. Spasticity grade (Y) was recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. Mean changes in spasticity grade (Y) from baseline to Week 4 are reported per cycle.","timeFrame":"Baseline and Week 4 of each cycle"},{"measure":"Use of Walking Aids/Orthoses at Baseline and Week 4","description":"Subjects were assessed on their use of walking aids and orthoses at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at the EOS/EW visit. Outcome measure is reported per cycle at baseline and Week 4. Number of subjects with no walking aid/orthoses were included in the 'No Walking Aid' category and number of subjects with any kind of walking aid/orthosis (including single point cane, tripod cane, ankle foot orthosis or other type of walking aid/orthosis) were combined into the 'Walking Aid' category.","timeFrame":"Baseline and Week 4 of each cycle"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of Dysport® Adult Lower Limb Spasticity Double Blind study Y-55-52120-140 (NCT01249404)\n\nExclusion Criteria:\n\n* Fixed contractures in lower limb","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ipsen Study Director","affiliation":"Ipsen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Mayo Clinic Arizona","city":"Scottsdale","state":"Arizona","zip":"85259","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Rancho Los Amigos","city":"Downey","state":"California","zip":"90242","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"facility":"Pacific Neuroscience Medical Group","city":"Oxnard","state":"California","zip":"93030","country":"United States","geoPoint":{"lat":34.1975,"lon":-119.17705}},{"facility":"Associated Neurologist of Southern CT, PC","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"Design Neuroscience Center","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Weill Cornell Medical College","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Island Neurological Associates","city":"Plainview","state":"New York","zip":"11803","country":"United States","geoPoint":{"lat":40.77649,"lon":-73.46735}},{"facility":"University of North Carolina - Chapel Hill","city":"Chapel Hill","state":"North Carolina","zip":"27599-7200","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Wake Forest University Baptist Medical Center","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Moss Rehab & Albert Einstein","city":"Elkins Park","state":"Pennsylvania","zip":"19027","country":"United States","geoPoint":{"lat":40.07706,"lon":-75.12684}},{"facility":"Vanderbilt University","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"The University of Texas Southwestern Medical Center at Dalla","city":"Dallas","state":"Texas","zip":"75390-9016","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"University of North Texas HSC at Ben Hogan Center","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"University of Texas - Houston","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Utah School of Medicine","city":"Salt Lake City","state":"Utah","zip":"84132","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"St George Hospital","city":"Kogarah","country":"Australia","geoPoint":{"lat":-33.98333,"lon":151.11667}},{"facility":"Epworth Rehabilitation","city":"Melbourne","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Royal Melbourne Hospital","city":"Melbourne","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"St Vincent's Hospital","city":"Melbourne","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"St Vincent's Hospital","city":"Sydney","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Westmead Hospital","city":"Sydney","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Université catholique de Louvain av Hippocrate 10","city":"Bruxelles","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Clinique Universitaire","city":"Yvoir","country":"Belgium","geoPoint":{"lat":50.3279,"lon":4.88059}},{"facility":"Charles University in Prague","city":"Praha 2","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"CHU Jean MINJOZ","city":"Besançon","country":"France","geoPoint":{"lat":47.24878,"lon":6.01815}},{"facility":"Centre de Réadaptation de Coubert","city":"Coubert","country":"France","geoPoint":{"lat":48.67186,"lon":2.69733}},{"facility":"Centre Hospitalier Albert Chenevier-Hopital Henri Mondor","city":"Créteil","country":"France","geoPoint":{"lat":48.78333,"lon":2.46667}},{"facility":"Hopital Raymond Poincarré","city":"Garches","country":"France","geoPoint":{"lat":48.84226,"lon":2.18232}},{"facility":"Hôpital de L'Archet I","city":"Nice","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"Hôpital Sébastopol","city":"Reims","country":"France","geoPoint":{"lat":49.25,"lon":4.03333}},{"facility":"Hôpital Civil","city":"Strasbourg","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Hopital Rangueil","city":"Toulouse","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"National Institute for Medical Rehabilitation","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Uno Medical Trials","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Petz Aladar Country Hospital","city":"Gyor","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Azienda Ospedaliero Universitaria \"Policlinico Vittorio Emanuele\"","city":"Catania","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Specjalistyczna Praktyka Lekarska","city":"Katowice","country":"Poland","geoPoint":{"lat":50.25841,"lon":19.02754}},{"facility":"Centrum Medyczne Plejady","city":"Krakow","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Krakowska Akademia Neurologii Sp. z o.o.","city":"Krakow","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Malopolskie Centrum Medyczne","city":"Krakow","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Nzoz Neuro - Card","city":"Poznan","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Samodzielny Publiczny Centralny Szpital Kliniczny","city":"Warszawa","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Serviço de Reabilitação","city":"Alcabideche","country":"Portugal","geoPoint":{"lat":38.73366,"lon":-9.40928}},{"facility":"Centro Hospitalar Lisboa Norte","city":"Lisbon","country":"Portugal","geoPoint":{"lat":38.71667,"lon":-9.13333}},{"facility":"Centro Hospitalar São João","city":"Porto","country":"Portugal","geoPoint":{"lat":41.14961,"lon":-8.61099}},{"facility":"Medical Rehabilitation Center","city":"Moscow","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Scientific Research Institute of Neurology","city":"Moscow","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"State University","city":"St Petersburg","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Derer's Hospital","city":"Bratislava","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Univerzitna nemocnica Bratislava","city":"Bratislava","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}}]},"referencesModule":{"references":[{"pmid":"32741133","type":"DERIVED","citation":"Esquenazi A, Brashear A, Deltombe T, Rudzinska-Bar M, Krawczyk M, Skoromets A, O'Dell MW, Grandoulier AS, Vilain C, Picaut P, Gracies JM. The Effect of Repeated abobotulinumtoxinA (Dysport(R)) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury. PM R. 2021 May;13(5):488-495. doi: 10.1002/pmrj.12459. Epub 2020 Sep 11."},{"pmid":"32108436","type":"DERIVED","citation":"Esquenazi A, Stoquart G, Hedera P, Jacinto LJ, Dimanico U, Constant-Boyer F, Brashear A, Grandoulier AS, Vilain C, Picaut P, Gracies JM. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial. PM R. 2020 Sep;12(9):853-860. doi: 10.1002/pmrj.12348. Epub 2020 Mar 27."},{"pmid":"31529136","type":"DERIVED","citation":"McAllister PJ, Khatkova SE, Faux SG, Picaut P, Raymond R, Gracies JM. Effects on walking of simultaneous upper/lower limb abobotulinumtoxina injections in patients with stroke or brain injury with spastic hemiparesis. J Rehabil Med. 2019 Oct 29;51(10):813-816. doi: 10.2340/16501977-2604."},{"pmid":"29093068","type":"DERIVED","citation":"Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017 Nov 28;89(22):2245-2253. doi: 10.1212/WNL.0000000000004687. Epub 2017 Nov 1."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of study participants.\n\nAny requests should be submitted to www.vivli.org for assessment by an independent scientific review board.","timeFrame":"Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.","accessCriteria":"Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).","url":"https://vivli.org/members/ourmembers/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 366 subjects completed Study 140, of which 352 subjects were enrolled in Study 142. Of these, 7 subjects entered an observational phase and never received open label treatment with Dysport® in Study 142 and the remaining 345 subjects started treatment and received at least one open label injection of Dysport® in Study 142.","recruitmentDetails":"The study was designed as a multicentre study and included 51 sites in Australia, Belgium, the Czech Republic, France, Hungary, Italy, Poland, Portugal, Russia, Slovakia and the United States of America that included at least one subject. The current study (Study 142) was an open label extension to the double blind Study 140 (Y-55-52120-140).","groups":[{"id":"FG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 Units \\[U\\] or 1000 U) by intramuscular (i.m.) injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"345"}]},{"type":"Cycle 1","achievements":[{"groupId":"FG000","numSubjects":"345"}]},{"type":"Cycle 2","achievements":[{"groupId":"FG000","numSubjects":"297"}]},{"type":"Cycle 3","achievements":[{"groupId":"FG000","numSubjects":"224"}]},{"type":"Cycle 4","achievements":[{"groupId":"FG000","numSubjects":"139"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"269"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"76"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"19"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"36"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"}]},{"type":"Subject Required Alternative Treatment","reasons":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"No Study Drug Available","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Subject had Personal or Medical Issues","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"End of Study Visit Performed in Error","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The summary of baseline characteristics presented are from subjects completing Study 140 who were selected by the investigator for entry into Study 142 and received at least one injection of study treatment in this open label extension study.","groups":[{"id":"BG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"345"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"280"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"65"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53.1","spread":"12.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"110"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"235"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"34"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"311"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"7"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"21"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"313"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)","description":"Adverse events (AEs) were monitored from the time that the subject gave informed consent to the end of the study/early withdrawal (EOS/EW). An AE was reported as a TEAE if it was not present prior to study treatment administration in Study 140, or if it was present prior to study treatment in Study 140 but the intensity increased during the treatment phase of this study. Adverse events of special interest (AESIs) were identified as those assessed as being due to remote spread of effect of Dysport®, or any AE that was assessed as a hypersensitivity reaction. TEAEs, treatment related TEAEs, severe TEAEs, TEAEs leading to death, TEAEs leading to withdrawal, treatment emergent AESIs, and serious adverse events (SAEs) are summarised by treatment cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Up to EOS (maximum duration of 52 weeks).","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"TEAE - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"140"}]}]},{"title":"TEAE - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97"}]}]},{"title":"TEAE - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}]},{"title":"TEAE - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]},{"title":"Treatment Related TEAE - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43"}]}]},{"title":"Treatment Related TEAE - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]},{"title":"Treatment Related TEAE - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Treatment Related TEAE - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Severe TEAE - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]},{"title":"Severe TEAE - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Severe TEAE - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Severe TEAE - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"TEAE leading to death - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"TEAE leading to death - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"TEAE leading to death - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"TEAE leading to death - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"TEAE leading to withdrawal - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"TEAE leading to withdrawal - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"TEAE leading to withdrawal - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"TEAE leading to withdrawal - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"AESI - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]},{"title":"AESI - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]},{"title":"AESI - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"AESI - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"SAE - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]},{"title":"SAE - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"SAE - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"SAE - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Systolic and Diastolic Blood Pressure (BP)","description":"Systolic and diastolic BP were recorded at baseline and at each subsequent study visit. BP was measured with the subject in a sitting position after resting for 3 minutes. Mean change in BP from baseline at Week 4 is reported per cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"Millimetres Mercury (mmHg)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Systolic BP - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","lowerLimit":"-67","upperLimit":"37"}]}]},{"title":"Systolic BP - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"281"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","lowerLimit":"-69","upperLimit":"37"}]}]},{"title":"Systolic BP - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","lowerLimit":"-58","upperLimit":"79"}]}]},{"title":"Systolic BP - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","lowerLimit":"-73","upperLimit":"25"}]}]},{"title":"Diastolic BP - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"-34","upperLimit":"37"}]}]},{"title":"Diastolic BP - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"281"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","lowerLimit":"-38","upperLimit":"30"}]}]},{"title":"Diastolic BP - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","lowerLimit":"-32","upperLimit":"28"}]}]},{"title":"Diastolic BP - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","lowerLimit":"-35","upperLimit":"32"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Heart Rate (HR)","description":"HR was recorded at baseline and at each subsequent study visit. HR was measured with the subject in a sitting position after resting for 3 minutes. Mean change in HR from baseline at Week 4 is reported per cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"Beats per minute (bpm)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","lowerLimit":"-28","upperLimit":"39"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"281"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"-27","upperLimit":"41"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"-25","upperLimit":"52"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"-16","upperLimit":"33"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Red Blood Cell (RBC) Count","description":"Blood samples for RBC count were taken at baseline, at Week 4, and at EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"Tera cells/Litre (L)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.049","lowerLimit":"-0.51","upperLimit":"0.66"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.074","lowerLimit":"-0.59","upperLimit":"0.68"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.046","lowerLimit":"-0.59","upperLimit":"0.66"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.028","lowerLimit":"-1.24","upperLimit":"0.61"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Haemoglobin and Mean Corpuscular Haemoglobin Concentration (MCHC)","description":"Blood samples for haemoglobin and MCHC were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"grams (g)/L","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Haemoglobin - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"-17","upperLimit":"32"}]}]},{"title":"Haemoglobin - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"-46","upperLimit":"25"}]}]},{"title":"Haemoglobin - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"-22","upperLimit":"26"}]}]},{"title":"Haemoglobin - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"-39","upperLimit":"17"}]}]},{"title":"MCHC - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"-29","upperLimit":"34"}]}]},{"title":"MCHC - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"-33","upperLimit":"41"}]}]},{"title":"MCHC - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"-23","upperLimit":"33"}]}]},{"title":"MCHC - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","lowerLimit":"-14","upperLimit":"37"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Haematocrit","description":"Blood samples for haematocrit were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"percentage of RBC in blood","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","lowerLimit":"-0.057","upperLimit":"0.081"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","lowerLimit":"-0.107","upperLimit":"0.098"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.001","lowerLimit":"-0.066","upperLimit":"0.086"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.009","lowerLimit":"-0.12","upperLimit":"0.047"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Mean Corpuscular Haemoglobin (MCH)","description":"Blood samples for MCH were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"picograms (pg)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","lowerLimit":"-4.7","upperLimit":"6.3"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","lowerLimit":"-9.3","upperLimit":"4.6"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"-2.8","upperLimit":"5.3"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","lowerLimit":"-1.8","upperLimit":"2"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Mean Corpuscular Volume (MCV)","description":"Blood samples for MCV were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"Femtolitres (fL)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","lowerLimit":"-10.3","upperLimit":"14.8"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","lowerLimit":"-21.2","upperLimit":"12.5"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","lowerLimit":"-8.5","upperLimit":"13.7"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.44","lowerLimit":"-9.1","upperLimit":"3.7"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in White Blood Cell (WBC) Count, Neutrophils, Lymphocytes and Platelets","description":"Blood samples for WBC count with differentials (neutrophils, lymphocytes) and platelet count were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"Giga cells/L","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"WBC count - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","lowerLimit":"-8.7","upperLimit":"5.3"}]}]},{"title":"WBC count - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","lowerLimit":"-5.7","upperLimit":"4.9"}]}]},{"title":"WBC count - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","lowerLimit":"-5.2","upperLimit":"5.1"}]}]},{"title":"WBC count - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","lowerLimit":"-4.3","upperLimit":"5.2"}]}]},{"title":"Neutrophils - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"304"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","lowerLimit":"-7.5","upperLimit":"4.5"}]}]},{"title":"Neutrophils - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"259"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","lowerLimit":"-5.3","upperLimit":"4.2"}]}]},{"title":"Neutrophils - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","lowerLimit":"-5.6","upperLimit":"4.8"}]}]},{"title":"Neutrophils - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","lowerLimit":"-4.4","upperLimit":"5.5"}]}]},{"title":"Lymphocytes - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","lowerLimit":"-1.3","upperLimit":"1.4"}]}]},{"title":"Lymphocytes - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","lowerLimit":"-1.3","upperLimit":"1.4"}]}]},{"title":"Lymphocytes - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"-1.2","upperLimit":"2.5"}]}]},{"title":"Lymphocytes - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","lowerLimit":"-0.9","upperLimit":"2"}]}]},{"title":"Platelets - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","lowerLimit":"-193","upperLimit":"192"}]}]},{"title":"Platelets - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"257"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-133","upperLimit":"276"}]}]},{"title":"Platelets - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"178"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"-139","upperLimit":"152"}]}]},{"title":"Platelets - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"-67","upperLimit":"167"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Alkaline Phosphatase (ALP), Gamma Glutamyl Transferase (GGT), Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT)","description":"Blood samples were taken at baseline, at Week 4, and at the EOS/EW for analysis of the following clinical chemistry parameters: ALP, GGT, SGOT and SGPT. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"IU/L","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"ALP - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","lowerLimit":"-60","upperLimit":"110"}]}]},{"title":"ALP - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","lowerLimit":"-141","upperLimit":"57"}]}]},{"title":"ALP - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","lowerLimit":"-238","upperLimit":"33"}]}]},{"title":"ALP - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","lowerLimit":"-45","upperLimit":"39"}]}]},{"title":"SGOT - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"-47","upperLimit":"35"}]}]},{"title":"SGOT - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3","lowerLimit":"-27","upperLimit":"144"}]}]},{"title":"SGOT - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"-109","upperLimit":"34"}]}]},{"title":"SGOT - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"-12","upperLimit":"19"}]}]},{"title":"SGPT - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"-60","upperLimit":"45"}]}]},{"title":"SGPT - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"-53","upperLimit":"302"}]}]},{"title":"SGPT - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"-444","upperLimit":"69"}]}]},{"title":"SGPT - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"-28","upperLimit":"25"}]}]},{"title":"GGT - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1","lowerLimit":"-122","upperLimit":"614"}]}]},{"title":"GGT - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","lowerLimit":"-145","upperLimit":"121"}]}]},{"title":"GGT - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3","lowerLimit":"-254","upperLimit":"107"}]}]},{"title":"GGT - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","lowerLimit":"-61","upperLimit":"70"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Total Bilirubin and Creatinine","description":"Blood samples for clinical chemistry analysis of total bilirubin and creatinine were taken at baseline, at Week 4, and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"Micromole/L (μmol/L)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Total bilirubin - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","lowerLimit":"-13.7","upperLimit":"12.8"}]}]},{"title":"Total bilirubin - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","lowerLimit":"-10.6","upperLimit":"15.2"}]}]},{"title":"Total bilirubin - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"-10.4","upperLimit":"7"}]}]},{"title":"Total bilirubin - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","lowerLimit":"-9.1","upperLimit":"16.1"}]}]},{"title":"Creatinine - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2","lowerLimit":"-36","upperLimit":"27"}]}]},{"title":"Creatinine - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","lowerLimit":"-36","upperLimit":"35"}]}]},{"title":"Creatinine - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","lowerLimit":"-53","upperLimit":"35"}]}]},{"title":"Creatinine - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.2","lowerLimit":"-62","upperLimit":"9"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in Blood Urea Nitrogen (BUN) and Fasting Blood Glucose","description":"Blood samples for analysis of BUN and fasting blood glucose levels were taken at baseline, at Week 4 and at the EOS/EW. Outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"millimole/L (mmol/L)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"BUN - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","lowerLimit":"-3.93","upperLimit":"5"}]}]},{"title":"BUN - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","lowerLimit":"-3.57","upperLimit":"5.72"}]}]},{"title":"BUN - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","lowerLimit":"-11.06","upperLimit":"4.29"}]}]},{"title":"BUN - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","lowerLimit":"-4.64","upperLimit":"3.57"}]}]},{"title":"Fasting blood glucose - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.046","lowerLimit":"-6.16","upperLimit":"6.38"}]}]},{"title":"Fasting blood glucose - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.009","lowerLimit":"-4.17","upperLimit":"9.44"}]}]},{"title":"Fasting blood glucose - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.015","lowerLimit":"-5.66","upperLimit":"7"}]}]},{"title":"Fasting blood glucose - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.231","lowerLimit":"-3.44","upperLimit":"8.61"}]}]}]},{"type":"PRIMARY","title":"Presence of Botulinum Toxin Type A (BTX-A) Neutralising Putative Antibodies (NAbs) Following Injection of Dysport®","description":"Blood samples were collected at baseline, Week 4 and at EOS/EW to test for the presence of BTX-A antibodies. The number of subjects who were either NAb positive at baseline or negative at baseline but then positive following injection of Dysport® were reported.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. In addition, the antibody analysis included subjects who had an antibody assessment at baseline and at a post baseline visit (n=343).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"At Week 4","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Positive at baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Negative at baseline & positive post baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Week 4 in 12-Lead Electrocardiogram (ECG)","description":"12-lead ECG tracing was performed at baseline, at Week 4 of each cycle and at EOS/EW. The 12-lead ECG recordings were performed at a paper speed of 25 millimetres/second (mm/s), recorded with the subject in a supine position after 5 minutes rest. The ECG parameters; QT Duration, QT interval corrected with Fridericia's method (QTcF), QT interval corrected with Bazett's method (QTcB), QRS duration and PR duration were recorded and outcome measure is reported per cycle as change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milliseconds (ms)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"324"}]}],"classes":[{"title":"QT Duration - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"24.9"}]}]},{"title":"QT Duration - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.2","spread":"22.9"}]}]},{"title":"QT Duration - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":"26.5"}]}]},{"title":"QT Duration - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.5","spread":"23.5"}]}]},{"title":"QTcF - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"16.9"}]}]},{"title":"QTcF - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"14.8"}]}]},{"title":"QTcF - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"16.2"}]}]},{"title":"QTcF - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"16.1"}]}]},{"title":"QTcB - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"20.2"}]}]},{"title":"QTcB - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"18.4"}]}]},{"title":"QTcB - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"19.5"}]}]},{"title":"QTcB - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"21.3"}]}]},{"title":"QRS Duration - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"6.3"}]}]},{"title":"QRS Duration - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"5.8"}]}]},{"title":"QRS Duration - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"6.2"}]}]},{"title":"QRS Duration - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"6.7"}]}]},{"title":"PR Duration - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"14.5"}]}]},{"title":"PR Duration - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"259"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"15.2"}]}]},{"title":"PR Duration - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"14.4"}]}]},{"title":"PR Duration - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"13.4"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in the Modified Ashworth Scale (MAS) Score Measured in the Gastrocnemius-soleus Complex (GSC) (Knee Extended)","description":"Muscle tone in the treated limb was assessed by MAS in the GSC (with the knee extended) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion (ROM)), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as mean change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.9"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"1"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in the MAS Measured in the Soleus Muscle (Knee Flexed)","description":"Muscle tone in the treated limb was assessed by MAS in the soleus muscle (with the knee flexed) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the ROM), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as mean change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"1.2"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With At Least a 1 or 2 Grade Reduction in the MAS Measured in the GSC (Knee Extended) at Week 4","description":"Muscle tone in the treated limb was assessed by MAS in the GSC (with the knee extended) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the ROM), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as the percentage of subjects with at least a 1 grade reduction or 2 grades reduction in MAS score at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"At least 1 grade reduction - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.2"}]}]},{"title":"At least 1 grade reduction - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.6"}]}]},{"title":"At least 1 grade reduction - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.7"}]}]},{"title":"At least 1 grade reduction - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.9"}]}]},{"title":"At least 2 grades reduction - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.3"}]}]},{"title":"At least 2 grades reduction - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.2"}]}]},{"title":"At least 2 grades reduction - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.2"}]}]},{"title":"At least 2 grades reduction - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With At Least a 1 or 2 Grade Reduction in the MAS Measured in the Soleus Muscle (Knee Flexed) at Week 4","description":"Muscle tone in the treated limb was assessed by MAS in the soleus muscle (with the knee flexed) at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. The MAS consists of 6 grades: 0 (no increase in muscle tone), 1 (slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the ROM), 1+ (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone) or 4 (affected part(s) rigid in flexion or extension), and can be applied to muscles of both the upper and lower limbs. Outcome measure is reported per cycle as the percentage of subjects with at least a 1 grade reduction or 2 grades reduction in MAS score at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"At least 1 grade reduction - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.4"}]}]},{"title":"At least 1 grade reduction - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.4"}]}]},{"title":"At least 1 grade reduction - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.3"}]}]},{"title":"At least 1 grade reduction - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.9"}]}]},{"title":"At least 2 grades reduction - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.4"}]}]},{"title":"At least 2 grades reduction - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.6"}]}]},{"title":"At least 2 grades reduction - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.4"}]}]},{"title":"At least 2 grades reduction - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.8"}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment (PGA) of Treatment Response at Week 4","description":"An assessment of overall treatment response was conducted by the investigator at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The investigator rated the response to treatment in the subject's lower limb after injection of Dysport® relative to the status at the baseline. Answers were made on a nine-point rating scale: -4=markedly worse, -3=much worse, -2=worse, -1=slightly worse, 0=no change, +1=slightly improved, +2=improved, +3=much improved, +4=markedly improved. The mean PGA scores per cycle at Week 4 were reported.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.1"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"216"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With a Score of at Least +1 on the PGA Scale at Week 4","description":"An assessment of overall treatment response was conducted by the investigator at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The investigator rated the response to treatment in the subject's lower limb after injection of Dysport® relative to the status at the baseline. Answers were made on a nine point rating scale: -4=markedly worse, -3=much worse, -2=worse, -1=slightly worse, 0=no change, +1=slightly improved, +2=improved, +3=much improved, +4=markedly improved. The percentage of responders with a PGA score of +1 or greater are reported at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.8"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.2"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.3"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.9"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in the Range of Active Ankle Dorsiflexion Both With the Knee Flexed and With the Knee Extended","description":"Range of active dorsiflexion of the ankle joint of the treated limb, measured using a goniometre, both with the knee flexed (90°) and extended, was used to assess treatment response. The measurements were obtained at the end of baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Degrees","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Knee Extended - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"10.6"}]}]},{"title":"Knee Extended - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"10.6"}]}]},{"title":"Knee Extended - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"11.4"}]}]},{"title":"Knee Extended - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"10.9"}]}]},{"title":"Knee Flexed - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"10.7"}]}]},{"title":"Knee Flexed - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"10.3"}]}]},{"title":"Knee Flexed - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"10.9"}]}]},{"title":"Knee Flexed - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Lower Limb Pain","description":"The intensity of lower limb pain in the treated limb was evaluated by the subject using the Scale of Pain Intensity (SPIN) which provided a pictorial representation of pain in a 6-point graphic scale with the degree of red shading inside a circle representing the intensity of pain. The bottom and top of the scale are anchored by two extremes: 'no pain' (circle with no red shading and scored as 0) and 'pain as bad as it could be' (circle completely red and scored as 5), marked with either verbal or visual cues. The intervening points are represented by red circles increasing proportionally in size. The subject marks the circle that best indicates their pain intensity. The SPIN assessments were obtained at baseline, Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at the EOS/EW. The mean changes from baseline in subjects with a baseline SPIN Score \\>0 at Week 4 was reported per cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.2"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.2"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.2"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Short Form (36) Health Survey (SF-36) Quality of Life (QoL)","description":"Subjects were asked to complete the SF-36 health surveys prior to the study treatment at baseline, at Week 4 and at the EOS/EW visit. The SF-36 is a generic non preference based health status measure. This instrument assessed subject health across 8 variable dimensions, which are specific health domains such as physical functioning, social functioning and vitality. Each variable item score is coded and turned into a 0-100 scale where 0 indicates the worst and 100 indicates the best possible health state for both the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the questionnaire. The mean change in the PCS and MCS from baseline to Week 4 are reported.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"PCS - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"330"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"7.5"}]}]},{"title":"PCS - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"7.67"}]}]},{"title":"PCS - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"7.01"}]}]},{"title":"PCS - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"6.65"}]}]},{"title":"MCS - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"330"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.13","spread":"11.27"}]}]},{"title":"MCS - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"12.7"}]}]},{"title":"MCS - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"12.24"}]}]},{"title":"MCS - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"13.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in European Quality of Life - 5 Dimensions, 5 Level (EQ-5D-5L) QoL","description":"Subjects were asked to complete the EQ-5D-5L QoL questionnaire prior to the study treatment at baseline, at Week 4 and at EOS/EW visit. The EQ-5D-5L index is a generic preference based measure of health related QoL producing utility scores that represent subject preferences for particular health states. This instrument rated subject health state looking at 5 specific dimensions such as mobility, self-care, usual activity, pain/discomfort and anxiety/ depression and scored their general health state. Each dimension has 5 levels of severity: no problems, slight problems, moderate problems, severe problems and extreme problems, rated from 1 to 5 (best to worst). In addition, a visual analogue scale (VAS) ranging from 0 to 100 was also included for the patients to summarize their overall health status, where 0 is the worst and 100 the best possible health state. The mean change in pain and discomfort and VAS scores from baseline to Week 4 are reported.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Pain/discomfort - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.0"}]}]},{"title":"Pain/discomfort - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.0"}]}]},{"title":"Pain/discomfort - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.0"}]}]},{"title":"Pain/discomfort - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.2"}]}]},{"title":"VAS - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"18.3"}]}]},{"title":"VAS - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"17.7"}]}]},{"title":"VAS - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"19.9"}]}]},{"title":"VAS - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"21.0"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Walking Speed (WS)","description":"All WS tests were conducted without walking aids over a distance of 10 metres at both a comfortable WS and at maximal WS. Evaluations of WS were made barefoot and with shoes on, at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"metres/second (m/s)","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Comfortable WS, barefoot - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.12"}]}]},{"title":"Comfortable WS, barefoot - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.13"}]}]},{"title":"Comfortable WS, barefoot - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.13"}]}]},{"title":"Comfortable WS, barefoot - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.14"}]}]},{"title":"Comfortable WS, with shoes - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.13"}]}]},{"title":"Comfortable WS, with shoes - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.14"}]}]},{"title":"Comfortable WS, with shoes - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.13"}]}]},{"title":"Comfortable WS, with shoes - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.14"}]}]},{"title":"Maximal WS, barefoot - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.16"}]}]},{"title":"Maximal WS, barefoot - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.18"}]}]},{"title":"Maximal WS, barefoot - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.18"}]}]},{"title":"Maximal WS, barefoot - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.18"}]}]},{"title":"Maximal WS, with shoes - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.17"}]}]},{"title":"Maximal WS, with shoes - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.19"}]}]},{"title":"Maximal WS, with shoes - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.19"}]}]},{"title":"Maximal WS, with shoes - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Step Length","description":"All WS tests were conducted without walking aids over a distance of 10 metres at both a comfortable WS and at maximal WS. Evaluations of step length were made barefoot and with shoes on, at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"m/step","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Comfortable WS, barefoot - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.06"}]}]},{"title":"Comfortable WS, barefoot - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.09"}]}]},{"title":"Comfortable WS, barefoot - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.08"}]}]},{"title":"Comfortable WS, barefoot - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.09"}]}]},{"title":"Comfortable WS, with shoes - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.07"}]}]},{"title":"Comfortable WS, with shoes - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.08"}]}]},{"title":"Comfortable WS, with shoes - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.08"}]}]},{"title":"Comfortable WS, with shoes - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.09"}]}]},{"title":"Maximal WS, barefoot - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.08"}]}]},{"title":"Maximal WS, barefoot - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.09"}]}]},{"title":"Maximal WS, barefoot - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.09"}]}]},{"title":"Maximal WS, barefoot - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.09"}]}]},{"title":"Maximal WS, with shoes - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.08"}]}]},{"title":"Maximal WS, with shoes - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.09"}]}]},{"title":"Maximal WS, with shoes - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.09"}]}]},{"title":"Maximal WS, with shoes - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Cadence","description":"All WS tests were conducted without walking aids over a distance of 10 metres at both a comfortable WS and at maximal WS. Evaluations of cadence were made barefoot and with shoes on, at baseline, at Weeks 4 and 12, at discretionary visits at Weeks 16, 20 and 24 of each cycle, and at EOS/EW. Outcome measure is reported per cycle as mean change from baseline at Week 4.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"steps/s","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Comfortable WS, barefoot - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.21"}]}]},{"title":"Comfortable WS, barefoot - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.23"}]}]},{"title":"Comfortable WS, barefoot - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.21"}]}]},{"title":"Comfortable WS, barefoot - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.21"}]}]},{"title":"Comfortable WS, with shoes - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.21"}]}]},{"title":"Comfortable WS, with shoes - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.22"}]}]},{"title":"Comfortable WS, with shoes - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.22"}]}]},{"title":"Comfortable WS, with shoes - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.21"}]}]},{"title":"Maximal WS, barefoot - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.26"}]}]},{"title":"Maximal WS, barefoot - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.28"}]}]},{"title":"Maximal WS, barefoot - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.26"}]}]},{"title":"Maximal WS, barefoot - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.25"}]}]},{"title":"Maximal WS, with shoes - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.23"}]}]},{"title":"Maximal WS, with shoes - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.27"}]}]},{"title":"Maximal WS, with shoes - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.27"}]}]},{"title":"Maximal WS, with shoes - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Angle of Arrest (XV1), Angle of Catch (XV3) and Spasticity Angle (X) in the GSC (Knee Extended)","description":"Spasticity in the treated limb was assessed using the Tardieu Scale (TS) for the GSC (knee extended). The TS is administered by applying passive stretch to a muscle group at two velocities. Slow speed of muscle stretch measures the range of passive motion. During a slow stretching movement, the examiner determines the angle of movement arrest, either due to subject discomfort or a mechanical resistance. The same movement is repeated at high velocity (as fast as possible) to determine the angle of catch and release. The angle of movement arrest at slow velocity (XV1) and the angle of catch at fast speed (XV3) were recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The spasticity angle (X) was calculated as the difference between XV1 and XV3. Mean changes in Angles XV1, XV3 and X from baseline to Week 4 are reported per cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Degrees","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Angle of arrest (XV1) - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"7.9"}]}]},{"title":"Angle of arrest (XV1) - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"7.8"}]}]},{"title":"Angle of arrest (XV1) - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"8.9"}]}]},{"title":"Angle of arrest (XV1) - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"8.4"}]}]},{"title":"Angle of catch (XV3) - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"10.6"}]}]},{"title":"Angle of catch (XV3) - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"11.1"}]}]},{"title":"Angle of catch (XV3) - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"12.2"}]}]},{"title":"Angle of catch (XV3) - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"12.4"}]}]},{"title":"Spasticity angle (X) - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"8.6"}]}]},{"title":"Spasticity angle (X) - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"9.2"}]}]},{"title":"Spasticity angle (X) - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"9.3"}]}]},{"title":"Spasticity angle (X) - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"9.2"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Spasticity Grade (Y) in the GSC (Knee Extended)","description":"Spasticity in the treated limb was assessed using the TS for the GSC (knee extended). The TS is administered by applying passive stretch to a muscle group. The spasticity grade (Y) assesses quality of muscle reaction on a 5-point scale (measured at fast speed): 0 =No resistance throughout passive movement, 1=slight resistance throughout passive movement, 2=clear catch at precise angle, interrupting passive movement, followed by release, 3=fatigable clonus (less than 10 seconds when maintaining pressure) occurring at a precise angle, followed by release. 4=unfatigable clonus (more than 10 seconds when maintaining pressure) occurring at precise angle. Spasticity grade (Y) was recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. Mean changes in spasticity grade (Y) from baseline to Week 4 are reported per cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.8"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.7"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.7"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Angle of Arrest (XV1), Angle of Catch (XV3) and Spasticity Angle (X) in the Soleus Muscle (Knee Flexed)","description":"Spasticity in the treated limb was assessed using the TS for the soleus muscle (knee flexed). The TS is administered by applying passive stretch to a muscle group at two velocities. Slow speed of muscle stretch measures the range of passive motion. During a slow stretching movement, the examiner determines the angle of movement arrest, either due to subject discomfort or a mechanical resistance. The same movement is repeated at high velocity (as fast as possible) to determine the angle of catch and release. The angle of movement arrest at slow velocity (XV1) and the angle of catch at fast speed (XV3) were recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. The spasticity angle (X) was calculated as the difference between XV1 and XV3. Mean changes in Angles XV1, XV3 and X from baseline to Week 4 are reported per cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Degrees","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Angle of arrest (XV1) - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"8.0"}]}]},{"title":"Angle of arrest (XV1) - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"8.1"}]}]},{"title":"Angle of arrest (XV1) - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"8.5"}]}]},{"title":"Angle of arrest (XV1) - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"8.6"}]}]},{"title":"Angle of catch (XV3) - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"10.3"}]}]},{"title":"Angle of catch (XV3) - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"10.8"}]}]},{"title":"Angle of catch (XV3) - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"11.2"}]}]},{"title":"Angle of catch (XV3) - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"11.4"}]}]},{"title":"Spasticity angle (X) - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"10.0"}]}]},{"title":"Spasticity angle (X) - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"9.8"}]}]},{"title":"Spasticity angle (X) - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"9.6"}]}]},{"title":"Spasticity angle (X) - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"11.1"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 4 in Spasticity Grade (Y) in the Soleus Muscle (Knee Flexed)","description":"Spasticity in the treated limb was assessed using the TS for the soleus muscle (knee flexed). The TS is administered by applying passive stretch to a muscle group. The spasticity grade (Y) assesses quality of muscle reaction on a 5-point scale (measured at fast speed): 0 =No resistance throughout passive movement, 1=slight resistance throughout passive movement, 2=clear catch at precise angle, interrupting passive movement, followed by release, 3=fatigable clonus (less than 10 seconds when maintaining pressure) occurring at a precise angle, followed by release. 4=unfatigable clonus (more than 10 seconds when maintaining pressure) occurring at precise angle. Spasticity grade (Y) was recorded at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at EOS/EW. Mean changes in spasticity grade (Y) from baseline to Week 4 are reported per cycle.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.8"}]}]},{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.7"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.8"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Use of Walking Aids/Orthoses at Baseline and Week 4","description":"Subjects were assessed on their use of walking aids and orthoses at baseline, at Weeks 4 and 12 after each Dysport® injection, at discretionary visits at Weeks 16, 20 and 24 of each cycle and at the EOS/EW visit. Outcome measure is reported per cycle at baseline and Week 4. Number of subjects with no walking aid/orthoses were included in the 'No Walking Aid' category and number of subjects with any kind of walking aid/orthosis (including single point cane, tripod cane, ankle foot orthosis or other type of walking aid/orthosis) were combined into the 'Walking Aid' category.","populationDescription":"Subjects who received at least one open label injection of Dysport® were included in this analysis population. The number of subjects with data available for analysis at each treatment cycle are reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline and Week 4 of each cycle","groups":[{"id":"OG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"classes":[{"title":"No Walking Aid at Baseline - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"101"}]}]},{"title":"Walking Aid at Baseline - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"345"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"244"}]}]},{"title":"No Walking Aid at Week 4 - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99"}]}]},{"title":"Walking Aid at Week 4 - Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"242"}]}]},{"title":"No Walking Aid at Baseline - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}]},{"title":"Walking Aid at Baseline - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"213"}]}]},{"title":"No Walking Aid at Week 4 - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}]},{"title":"Walking Aid at Week 4 - Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"212"}]}]},{"title":"No Walking Aid at Baseline - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}]},{"title":"Walking Aid at Baseline - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"168"}]}]},{"title":"No Walking Aid at Week 4 - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59"}]}]},{"title":"Walking Aid at Week 4 - Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"147"}]}]},{"title":"No Walking Aid at Baseline - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]},{"title":"Walking Aid at Baseline - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99"}]}]},{"title":"No Walking Aid at Week 4 - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}]},{"title":"Walking Aid at Week 4 - Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From baseline to EOS (maximum duration of 52 weeks).","description":"AE data is reported as TEAEs. An AE was reported as a TEAE if it arose or the intensity increased during the treatment phase of this study.","eventGroups":[{"id":"EG000","title":"Total Dysport®","description":"Subjects who had completed Study 140 were offered to continue to receive open label treatment with Dysport® in Study 142 for a maximum of 4 additional treatment cycles, with a minimum interval of 12 weeks between treatment cycles. All subjects were administered an appropriate dosage of Dysport® (1500 U or 1000 U) by i.m. injection in the lower limb on Day 1 of treatment Cycle 1. In all cases, the administration of the Dysport® injections was limited to a maximum dose of 1500 U every 12 weeks. Follow up visits were timed to assess the onset and progression of treatment response. From treatment Cycle 3 onwards, subjects with co-existing upper limb spasticity were able to receive concomitant injections of Dysport® into at least one upper limb muscle at a dose not exceeding 500 U. Dysport® contains the neurotoxin Clostridium botulinum type A toxin-haemagglutinin complex (abobotulinumtoxinA).","seriousNumAffected":43,"seriousNumAtRisk":345,"otherNumAffected":69,"otherNumAtRisk":345}],"seriousEvents":[{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Subdural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Coronary artery dissection","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":345}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Death","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":345}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":345}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":345}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":345}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Death","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":345}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Intestinal polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":345}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":345}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":345}]}],"otherEvents":[{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":42,"numAtRisk":345}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (18.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":36,"numAtRisk":345}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Data is summarised according to total dose received at each corresponding cycle (i.e. including 1000 U and 1500 U Dysport® in lower limb during all cycles, as well as 1000 U in lower limb + 500 U Dysport® in upper limb during Cycles 3 and 4)."},"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Medical Director, Neurology,","organization":"Ipsen","email":"clinical.trials@ipsen.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Czech Republic"]},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000001930","term":"Brain Injuries"},{"id":"D000070642","term":"Brain Injuries, Traumatic"}],"ancestors":[{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000006259","term":"Craniocerebral Trauma"},{"id":"D000020196","term":"Trauma, Nervous System"},{"id":"D000014947","term":"Wounds and Injuries"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4897","name":"Brain Injuries","asFound":"Brain Injury","relevance":"HIGH"},{"id":"M628","name":"Brain Injuries, Traumatic","asFound":"Traumatic Brain Injury","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17375","name":"Wounds and Injuries","relevance":"LOW"},{"id":"M9039","name":"Craniocerebral Trauma","relevance":"LOW"},{"id":"M21713","name":"Trauma, Nervous System","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Baricitinib","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}